[Kidney transplantation before starting dialysis therapy].
The rate of the clinical adoption of the so-called pre-emptive transplantation is widely different among countries. In North America it represents 25 % of the total living donor transplantations; in Norway and Sweden it is 15 % and 9 %, respectively, of all grafts performed; in Italy it is less than 1%, whilst in countries like Austria, Germany and Ireland pre-emptive transplantation is nonexistent. Some concern on this type of transplantation was raised in the Seventies and were mainly based on the evidence that uraemia has an immunosuppressive effect, which could be weaker in the pre-dialysis period. Several clinical observations in the pre- cyclosporin era supported this assumption. Starting from the Eighties, however, several studies have demonstrated that pre-emptive transplantation may yield better recipient and graft survival. Moreover, a recent retrospective study, based on higher than 8000 living donor grafts that included both treated and untreated by long-term dialysis before transplantation, showed in the pre-emptive cohort a 52 % reduction in graft losses after the first year and also a lower incidence of acute rejections. Among the advantages of pre-emptive transplantation we find better rehabilitation and especially a lower risk of job loss. The risk of poorer patient compliance, as initially pointed out, has no longer been reported and can be overcome by adequate psychological preparation of the patient. Most centres performing pre-emptive transplantation favour the use of living donor because of the general shortage of cadaver kidney vs. the increasing number of dialysed patients on the waiting list. Nevertheless, in special circumstances (national programs with short waiting lists, uremic type I diabetics, children, primary type I hyperoxaluria), some AA also recommend the use of the cadaver donor.
Cattedra di Nefrologia dell'Universita' di Torino - Centro Trapianti Renali U.O.A.D.U. Nefrologia Dialisi e Trapianto - Azienda Ospedaliera S. Giovanni di Torino, Torino, Italy.
G P
GP
Segoloni
G B
GB
Piccoli
G
G
Leonardi
D000328:Adult; D002648:Child; D003131:Combined Modality Therapy; D005060:Europe; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy; D007676:Kidney Failure, Chronic / Q000276:immunology / Q000601:surgery* / Q000628:therapy; D016030:Kidney Transplantation / Q000009:adverse effects / Q000379:methods / Q000706:statistics & numerical data; D015993:Life Tables; D009656:North America; D011788:Quality of Life; D006435:Renal Dialysis; D012189:Retrospective Studies; D012306:Risk; D016019:Survival Analysis; D014019:Tissue Donors; D016896:Treatment Outcome